• Home
  • Top Stories
  • Markets
  • Market Data
  • Companies
  • Opinion
  • Economy & Policy
  • Finance
  • Politics
  • Technology
  • Personal Finance
  • Current Affairs
  • International
  • Management
  • Weekend
  • General News
  • Latest News
  • Today's Paper
  • Videos
  • Covid-19
  • Portfolio
  • Login

Pharmaceuticals
Essentials tag unlikely to benefit pharmaceutical companies in Q1
Top govt scientists tell MPs Covid-19 vaccine at least a year away
Cipla set to undercut rivals with low-priced generic remdesivir: Report
Despite poor show in Q4, India Inc's combined dividend payout rises 6.5%
DRL to launch innovator brand of favipiravir, is silent on pricing

Pharmaceuticals body seeks faster clearances of imported goods at ports
Gilead prices Covid-19 drug remdesivir at $2,340 in developed nations
Infosys launches personalised medicine solution for pharmaceutical cos
Sun Pharma to launch its first innovative product for psoriasis in Japan
The oil factor

Is India right in recommending HCQ despite the uncertainties around it?
Sanofi stops enrolling Covid-19 patients in hydroxychloroquine trials
Lupin reports 25% fall in pre-tax profit at Rs 412 cr in Q4 on low sales
Specialty products segment key to Sun Pharma's growth prospects
Pharma, chemical stocks lead under lockdown, Aurobindo is top performer
'Talk to experts to make self-reliant slogan work'
Covid-19: ICMR issues guidance on antibody test kits, lists manufacturers
Covid-19: Lockdown exit plans highlight divergence in emerging markets
Opportunity for Make in India
Investors should stick to stocks of firms focused on domestic market
Next 
⇧ Back to Top
  • Top Stories
  • Markets
  • Market Data
  • Companies
  • Opinion
  • Economy & Policy
  • Finance
  • Politics
  • Technology
  • Personal Finance
  • Current Affairs
  • International
  • Budget 2021
  • Insurance Round Table 2020
View Full Site >>
Copyrights © 2021 Business Standard Private Ltd. All rights reserved